$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024035400 Filed on August 07, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue		$14.64M	$0.00
YoY Change
Cost Of Revenue		$636.0K
YoY Change
Gross Profit		$14.00M
YoY Change
Gross Profit Margin		95.66%
Selling, General & Admin		$105.4M	$46.54M
YoY Change		490.91%	219.68%
% of Gross Profit		753.09%
Research & Development		$71.09M	$70.64M
YoY Change		3.62%	-0.14%
% of Gross Profit		507.72%
Depreciation & Amortization		$267.0K	$142.0K
YoY Change		111.9%	10.08%
% of Gross Profit		1.91%
Operating Expenses		$177.2M	$117.2M
YoY Change		104.95%	37.37%
Operating Profit		-$162.5M	-$117.2M
YoY Change		88.01%	37.37%
Interest Expense		$3.656M	$3.971M
YoY Change		26.03%	136.09%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income		-$152.0M	-$112.2M
YoY Change		77.12%	30.6%
Income Tax
% Of Pretax Income
Net Earnings		-$152.0M	-$112.2M
YoY Change		77.12%	30.6%
Net Earnings / Revenue		-1038.2%
Basic Earnings Per Share		-$7.10	-$5.68
Diluted Earnings Per Share		-$7.10	-$5.68
COMMON SHARES
Basic Shares Outstanding	21.71M shares	21.31M shares	19.74M
Diluted Shares Outstanding		21.40M shares	19.76M shares

Balance Sheet

Concept	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.058B	$634.1M
YoY Change	254.47%	76.75%
Cash & Equivalents	$494.6M	$99.92M
Short-Term Investments	$563.2M	$534.2M
Other Short-Term Assets		$3.150M
YoY Change		21.39%
Inventory	$7.072M	$0.00
Prepaid Expenses
Receivables	$6.899M	$0.00
Other Receivables
Total Short-Term Assets	$1.092B	$637.3M
YoY Change	261.98%	76.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.695M	$1.553M
YoY Change	272.53%	158.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$8.061M	$3.266M
YoY Change	830.83%	171.49%
TOTAL ASSETS
Total Short-Term Assets	$1.092B	$637.3M
Total Long-Term Assets	$8.061M	$3.266M
Total Assets	$1.100B	$640.5M
YoY Change	263.61%	76.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.994M	$28.04M
YoY Change	-48.71%	17.67%
Accrued Expenses	$115.6M	$89.98M
YoY Change	41.4%	-1.62%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$125.2M	$118.5M
YoY Change	25.53%	2.29%
LONG-TERM LIABILITIES
Long-Term Debt	$116.6M	$115.5M
YoY Change	17.49%	134.29%
Other Long-Term Liabilities		$1.186M
YoY Change
Total Long-Term Liabilities	$117.5M	$116.7M
YoY Change	18.4%	136.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$125.2M	$118.5M
Total Long-Term Liabilities	$117.5M	$116.7M
Total Liabilities	$242.7M	$235.2M
YoY Change	21.97%	42.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.636B	-$1.336B
YoY Change	45.4%	38.81%
Common Stock	$2.493B	$1.741B
YoY Change	102.88%	50.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$857.1M	$405.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.100B	$640.5M
YoY Change	263.61%	76.67%

Cashflow Statement

Concept	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$152.0M	-$112.2M
YoY Change	77.12%	30.6%
Depreciation, Depletion And Amortization	$267.0K	$142.0K
YoY Change	111.9%	10.08%
Cash From Operating Activities	-$134.9M	-$79.93M
YoY Change	79.19%	36.6%
INVESTING ACTIVITIES
Capital Expenditures	$5.131M	$1.036M
YoY Change	7336.23%	3472.41%
Acquisitions
YoY Change
Other Investing Activities	-$117.0M	-$361.1M
YoY Change	3093.2%	-643.67%
Cash From Investing Activities	-$122.1M	-$362.1M
YoY Change	3171.65%	-645.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	134.1M	479.9M
YoY Change	212.42%	81.55%
NET CHANGE
Cash From Operating Activities	-134.9M	-79.93M
Cash From Investing Activities	-122.1M	-362.1M
Cash From Financing Activities	134.1M	479.9M
Net Change In Cash	-122.9M	37.86M
YoY Change	240.39%	-86.09%
FREE CASH FLOW
Cash From Operating Activities	-$134.9M	-$79.93M
Capital Expenditures	$5.131M	$1.036M
Free Cash Flow	-$140.1M	-$80.97M
YoY Change	85.83%	38.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-196000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-151971000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	857120000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	987000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11813000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	25631000	usd
	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-11258000	usd
	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-3562000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-284102000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-159377000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	290696000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33277
	dei	Entity Registrant Name EntityRegistrantName	MADRIGAL PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3508648
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Four Tower Bridge
	dei	Entity Address Address Line2 EntityAddressAddressLine2	200 Barr Harbor Drive, Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	West Conshohocken
	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19428
	dei	City Area Code CityAreaCode	267
	dei	Local Phone Number LocalPhoneNumber	824-2827
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value Per Share
	dei	Trading Symbol TradingSymbol	MDGL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21712677	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	494597000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99915000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	5000000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	563197000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	534216000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6899000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	7072000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14963000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3150000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	1091728000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	637281000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1695000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1553000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4910000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1456000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1713000	usd
CY2024Q2	us-gaap	Assets Assets	1099789000	usd
CY2023Q4	us-gaap	Assets Assets	640547000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8994000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28041000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	115611000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	557000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	527000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	125162000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118548000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	116607000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	115480000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	900000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1186000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	117507000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	116666000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	242669000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	235214000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21700893	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21700893	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19875427	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19875427	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2493288000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1741153000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-368000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	468000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1635802000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1336290000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	857120000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	405333000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1099789000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	640547000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14638000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14638000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	636000	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	636000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
CY2024Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	71091000	usd
CY2023Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	68605000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	142328000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	130759000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	105448000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17845000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	186249000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34027000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	177175000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	86450000	usd
	us-gaap	Operating Expenses OperatingExpenses	329213000	usd
	us-gaap	Operating Expenses OperatingExpenses	164786000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-162537000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-86450000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-314575000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-164786000	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	14222000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3551000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	22556000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7327000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	3656000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	2901000	usd
	us-gaap	Interest Expense InterestExpense	7493000	usd
	us-gaap	Interest Expense InterestExpense	5237000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-151971000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-85800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-299512000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-162696000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.10
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.10
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.69
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.91
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21402646	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21402646	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18310952	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18310952	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20702041	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20702041	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18249778	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18249778	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-151971000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-85800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-299512000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-162696000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-196000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-836000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-57000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-152167000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85803000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-300348000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-162753000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	405333000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	311560000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	19902000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-640000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147541000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	850759000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	85950000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	24404000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	197389000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11250000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-54000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	544000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	150136000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21754000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	10973000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	195000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-85800000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103506000	usd
	us-gaap	Profit Loss ProfitLoss	-299512000	usd
	us-gaap	Profit Loss ProfitLoss	-162696000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	44306000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	22223000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	435000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	250000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1127000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6899000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	582000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7072000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-19047000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-6297000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9700000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	364988000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	346431000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	100204000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	488000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24045000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-190596000	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	50000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	288000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	707829000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95620000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	399682000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-254353000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99915000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	331549000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	499597000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77196000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.02
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	mdgl	Deferred Tax Assets Percentage Of Valuation Allowance DeferredTaxAssetsPercentageOfValuationAllowance	1
	us-gaap	Net Income Loss NetIncomeLoss	-299500000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1635800000	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	574000000	usd
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	85900000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	5000000.0	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	499597000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	499597000	usd
CY2024Q2	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	1063162000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	373000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1062794000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	633663000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	476000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	634131000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5728000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1344000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	7072000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q2	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	65473000	usd
CY2023Q4	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	50737000	usd
CY2024Q2	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	4206000	usd
CY2023Q4	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	3724000	usd
CY2024Q2	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	2045000	usd
CY2023Q4	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	9705000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21341000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17030000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	15496000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6814000	usd
CY2024Q2	mdgl	Accrued Expenses Gross AccruedExpensesGross	1931000	usd
CY2023Q4	mdgl	Accrued Expenses Gross AccruedExpensesGross	0	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5119000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1970000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	115611000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14899	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	600000	usd
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	900000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	6400000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	12768000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	79604000	usd
CY2024Q2	mdgl	Long Term Debt Maturity After Year Two LongTermDebtMaturityAfterYearTwo	53387000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	152159000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	31007000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4545000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	116607000	usd
	mdgl	Common Stock Voting Rights Number CommonStockVotingRightsNumber	1	vote
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2355779	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	148970	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	232.88
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	671947	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	73.91
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	59995	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	118.98
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1772807	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	93.76
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1323994	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	79.14
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24404000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10973000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44306000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22223000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24404000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10973000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44306000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22223000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	149100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M2D
	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1600000	usd
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-035400-index-headers.html	Edgar Link	pending
0001628280-24-035400-index.html	Edgar Link	pending
0001628280-24-035400.txt	Edgar Link	pending
0001628280-24-035400-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mdgl-20240630.htm	Edgar Link	pending
mdgl-20240630.xsd	Edgar Link	pending
mdgl-20240630xex311.htm	Edgar Link	pending
mdgl-20240630xex312.htm	Edgar Link	pending
mdgl-20240630xex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mdgl-20240630_cal.xml	Edgar Link	unprocessable
mdgl-20240630_def.xml	Edgar Link	unprocessable
mdgl-20240630_lab.xml	Edgar Link	unprocessable
mdgl-20240630_pre.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mdgl-20240630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

2024 Q3 Form 10-Q Financial Statement

#000162828024035400 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL Madrigal Pharmaceuticals Inc Stock $mdgl

2024 Q3 Form 10-Q Financial Statement

#000162828024035400 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl